Pharmaceuticals Thailand

Thailand Hyperuricemia Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Thailand Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Thailand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.8 Mn Placeholder estimate
Estimate 2025 $3.0 Mn 0.1% of the global market
Projected 2034 $5.6 Mn 88.5% Adds $2.7 Mn over 9 forecast years
CAGR 2025–2034 7.3% Faster than 36% of 180 Pharmaceuticals markets here
Key players 5
  • Thailand is 0.11% of the global market.
  • In APAC, the largest is China at $206.3 Mn.
  • Fastest growing: India at 10.2% a year.
  • Thailand ranks 10th of 10 by size in APAC.

Market size projection

Thailand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hyperuricemia Drugs Market market size by year, Thailand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.8 Mn — —
2025 (base) $3.0 Mn +$0.2 Mn —
2026 (forecast) $3.2 Mn +$0.2 Mn +7.3%
2027 (forecast) $3.4 Mn +$0.2 Mn +15.1%
2028 (forecast) $3.7 Mn +$0.3 Mn +23.5%
2029 (forecast) $4.0 Mn +$0.3 Mn +32.6%
2030 (forecast) $4.3 Mn +$0.3 Mn +42.2%
2031 (forecast) $4.6 Mn +$0.3 Mn +52.6%
2032 (forecast) $4.9 Mn +$0.3 Mn +63.8%
2033 (forecast) $5.3 Mn +$0.4 Mn +75.7%
2034 (forecast) $5.6 Mn +$0.4 Mn +88.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Thailand Hyperuricemia Drugs Market Analysis at a glance
Market size, 2025$3.0 Mn placeholder estimate
Forecast, 2034$5.6 Mn placeholder estimate
Growth (CAGR), 2025–20347.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin, Arthrosi Therapeutics (see all)
Regulator in ThailandThai FDASource: Thai Food and Drug Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Thailand Hyperuricemia Drugs Market Analysis Executive Summary

Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.

Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).

Bar chart: Thailand Hyperuricemia Drugs market size, 2024–2034, placeholder estimates. $2.8 Mn in 2024, $3.0 Mn in 2025 and $5.6 Mn in 2034, 7.3% CAGR.
Thailand Hyperuricemia Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Thailand Hyperuricemia Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Hyperuricemia Drugs Market in Thailand

The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hyperuricemia Drugs Market in Thailand

Hyperuricemia Drugs in Thailand: rules and payment

Medicines need registration with the Thai Food and Drug Administration (Thai FDA).⁠[1] The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes.⁠[2]

[1] Thai Food and Drug Administration. Checked 14 Nov 2026.

[2] National Health Security Office. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Thailand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hyperuricemia Drugs in context

Thailand compared

  • Health spending per person: 327 US$ per person (2023). World: 1,317 US$ per person (2023). 7th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.54 per 1,000 people (2021). World: 1.86 per 1,000 people (2022). 13th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 16.0% of people (2025). World: 10.4% of people (2025). 5th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hyperuricemia Drugs market in Thailand?
Placeholder estimate: about $3.0 Mn in 2025, rising to about $5.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hyperuricemia Drugs market in Thailand growing?
Placeholder estimate: about 7.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hyperuricemia Drugs market report cover?
The report splits the market by drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors, Recombinant Uricase), indication (Gout, Chronic Kidney Disease, Tumor Lysis Syndrome) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Hyperuricemia Drugs market?
Key players include Takeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin and Arthrosi Therapeutics.
What is driving the Hyperuricemia Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market.
Who regulates Hyperuricemia Drugs in Thailand?
Medicines need registration with the Thai Food and Drug Administration (Thai FDA). Source: Thai Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in Thailand?
The Universal Coverage Scheme, run by the National Health Security Office (NHSO), covers people outside the social security and civil servant schemes. Source: National Health Security Office. Checked 14 Nov 2026.
How much research is published on Hyperuricemia Drugs?
PubMed lists 2,548 papers on Hyperuricemia Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Thailand

See all

Related on kidney health

See the topic